ERBB2 and esophageal adenocarcinoma: While further in vitro studies and clinical validation will be needed, our findings suggest that characterization of IGFBP2 expression could inform treatment selection for subjects with esophageal adenocarcinoma, particularly for the majority of patients whose tumors do not demonstrate HER2/neu overexpression.